ZyVersa Therapeutics (ZVSA) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing drugs for chronic renal and inflammatory diseases with high unmet medical needs.

• Two proprietary drug development platforms: VAR 200 (for renal diseases) and IC 100 (for inflammatory conditions), both licensed from University of Miami-affiliated entities.

• Lead renal candidate VAR 200 is advancing to Phase 2a trials for diabetic kidney disease in H2 2024, with plans for FSGS indication expansion.

• IC 100 is nearing completion of preclinical development, with an IND submission planned for Q4-2024 targeting obesity with metabolic complications.

• Strategy focuses on indication expansion to maximize commercial potential, with ongoing preclinical studies in multiple disease areas.

Financial performance and metrics

• As of August 30, 2024, aggregate market value of outstanding common stock held by non-affiliates was approximately $2,969,961, based on 1,072,188 shares at $2.77 per share.

• Company is classified as a smaller reporting company and an emerging growth company.

• Auditors have included a going concern explanatory paragraph in their reports for 2022 and 2023.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.